Free question archive
One cited question a day, kept forever. Answer today's on the daily page.
Breast
- Breast: Adjuvant chemotherapy and genomic assays · 26 October 2026
- Breast: Adjuvant endocrine therapy (ovarian suppression) · 15 October 2026
- Breast: DCIS management and radiotherapy · 04 October 2026
- Breast: Metastatic HER2-positive and CDK4/6 · 23 September 2026
- Breast: Axillary management (AMAROS) · 12 September 2026
- Breast: Axillary management (Z0011) · 01 September 2026
- Breast: Post-mastectomy radiotherapy · 21 August 2026
- Breast: Tumour-bed boost · 10 August 2026
- Breast: FAST-Forward 5-fraction radiotherapy · 30 July 2026
- Breast: Whole-breast hypofractionation · 19 July 2026
Miscellaneous
- Miscellaneous: Bone sarcoma: osteosarcoma chemotherapy · 25 October 2026
- Miscellaneous: Bone sarcoma: Ewing chemotherapy (Euro Ewing 2012) · 14 October 2026
- Miscellaneous: Palliative RT: single-fraction bone metastases · 03 October 2026
- Miscellaneous: Applied biostatistics: number needed to treat · 22 September 2026
- Miscellaneous: Oncological emergency: neutropenic sepsis · 11 September 2026
- Miscellaneous: Oncological emergency: MSCC · 31 August 2026
- Miscellaneous: CUP: favourable subsets · 20 August 2026
- Miscellaneous: Neuroendocrine tumour: PRRT (NETTER-1) · 09 August 2026
- Miscellaneous: Soft-tissue sarcoma: neoadjuvant vs adjuvant RT · 29 July 2026
Skin
- Skin: Sentinel node biopsy threshold by Breslow thickness · 24 October 2026
- Skin: Wide local excision margin for thin melanoma · 13 October 2026
- Skin: AJCC8 melanoma M staging and CNS disease · 02 October 2026
- Skin: AJCC8 melanoma T staging · 21 September 2026
- Skin: Role of radiotherapy in non-melanoma skin cancer · 10 September 2026
- Skin: Adjuvant systemic therapy stage III and BRAF testing · 30 August 2026
- Skin: Management of a positive sentinel lymph node · 19 August 2026
- Skin: Sentinel lymph node biopsy indication · 08 August 2026
- Skin: Excision margins by Breslow thickness · 28 July 2026
Haematology
- Haematology: Advanced Hodgkin: interim-PET-positive escalation (RATHL) · 23 October 2026
- Haematology: Early-stage Hodgkin: combined-modality vs PET-adaptation (RAPID synthesis) · 12 October 2026
- Haematology: Gastric MALT lymphoma management · 01 October 2026
- Haematology: Stage I follicular lymphoma: curative-intent RT dose · 20 September 2026
- Haematology: Follicular lymphoma: low-dose palliative RT (4 Gy / 2 fractions) · 09 September 2026
- Haematology: Involved-site radiotherapy concept · 29 August 2026
- Haematology: Advanced Hodgkin: response-adapted therapy (RATHL) · 18 August 2026
- Haematology: Early-stage Hodgkin: PET-adapted involved-node RT (H10) · 07 August 2026
- Haematology: Early-stage Hodgkin: combined-modality vs chemotherapy alone (RAPID) · 27 July 2026
Upper GI
- Upper GI: Gastric HER2-positive metastatic disease (ToGA) · 22 October 2026
- Upper GI: Definitive chemoRT for oesophageal SCC - dose and concurrent chemotherapy · 11 October 2026
- Upper GI: Oesophageal neoadjuvant chemoRT vs perioperative chemo - histology · 30 September 2026
- Upper GI: Palliative measures - dysphagia and bleeding · 19 September 2026
- Upper GI: HCC - BCLC staging and systemic therapy · 08 September 2026
- Upper GI: MAGIC trial - perioperative chemotherapy principle · 28 August 2026
- Upper GI: Perioperative chemotherapy gastric (FLOT4 vs MAGIC) · 17 August 2026
- Upper GI: Definitive chemoRT for oesophageal SCC · 06 August 2026
- Upper GI: Oesophageal neoadjuvant chemoradiotherapy (CROSS) · 26 July 2026
Gynaecology
- Gynaecology: Cervix — immunotherapy with chemoradiotherapy (KEYNOTE-A18) · 21 October 2026
- Gynaecology: Cervix — para-aortic nodal staging and management · 10 October 2026
- Gynaecology: Cervix — image-guided adaptive brachytherapy outcomes (EMBRACE-I) · 29 September 2026
- Gynaecology: Ovarian — first-line adjuvant chemotherapy and maintenance · 18 September 2026
- Gynaecology: Endometrial — role of radiotherapy in stage I · 07 September 2026
- Gynaecology: Endometrial — adjuvant management by risk group · 27 August 2026
- Gynaecology: Cervix — concurrent chemoradiotherapy evidence · 16 August 2026
- Gynaecology: Cervix — FIGO 2018 staging · 05 August 2026
- Gynaecology: Locally advanced cervix — definitive chemoradiotherapy · 25 July 2026
Central nervous system
- CNS: Meningioma observation · 20 October 2026
- CNS: WHO 2021 molecular classification · 09 October 2026
- CNS: Meningioma grading and RT indications · 28 September 2026
- CNS: QUARTZ and WBRT in NSCLC metastases · 17 September 2026
- CNS: Brain metastases SRS vs WBRT · 06 September 2026
- CNS: Low-grade glioma risk stratification · 26 August 2026
- CNS: Elderly glioblastoma · 15 August 2026
- CNS: MGMT and IDH significance · 04 August 2026
- CNS: Glioblastoma standard of care · 24 July 2026
Lower GI
- Lower GI: Total neoadjuvant therapy (PRODIGE-23) · 19 October 2026
- Lower GI: Rectal MRI risk stratification and neoadjuvant selection · 08 October 2026
- Lower GI: Metastatic colorectal cancer molecular markers · 27 September 2026
- Lower GI: Anal cancer salvage and response assessment · 16 September 2026
- Lower GI: Anal cancer definitive chemoradiotherapy · 05 September 2026
- Lower GI: Total neoadjuvant therapy (FOLFIRINOX) · 25 August 2026
- Lower GI: Preoperative versus postoperative chemoradiotherapy · 14 August 2026
- Lower GI: MRI risk stratification for neoadjuvant therapy · 03 August 2026
- Lower GI: Indications for neoadjuvant radiotherapy by stage · 23 July 2026
Head & neck
- Head & neck: Oropharynx de-escalation — RTOG 1016 locoregional control · 18 October 2026
- Head & neck: Oropharynx — definitive chemoRT and altered fractionation · 07 October 2026
- Head & neck: Oropharynx — HPV/p16 TNM8 staging · 26 September 2026
- Head & neck: Nasopharyngeal carcinoma — chemoRT · 15 September 2026
- Head & neck: Postoperative indications for concurrent chemoRT — high-risk features · 04 September 2026
- Head & neck: Postoperative indications for concurrent chemoRT · 24 August 2026
- Head & neck: Oropharynx — de-intensification and trial enrolment · 13 August 2026
- Head & neck: Oropharynx — definitive concurrent chemoRT (HPV-positive) · 02 August 2026
- Head & neck: Oropharynx — HPV/p16 prognostic significance · 22 July 2026
Urology
- Urology: Post-prostatectomy radiotherapy timing (RADICALS-RT) · 17 October 2026
- Urology: Prostate radical RT hypofractionation and concurrent ADT · 06 October 2026
- Urology: Stage I seminoma management · 25 September 2026
- Urology: Upper-tract urothelial adjuvant chemotherapy · 14 September 2026
- Urology: Muscle-invasive bladder neoadjuvant chemotherapy · 03 September 2026
- Urology: Muscle-invasive bladder bladder-preservation chemoRT · 23 August 2026
- Urology: Low-risk prostate active surveillance · 12 August 2026
- Urology: Prostate ADT duration with radical RT · 01 August 2026
- Urology: Prostate radical RT hypofractionation · 21 July 2026
Respiratory
- Lung: ADAURA - disease-free survival magnitude · 16 October 2026
- Lung: Adjuvant osimertinib (ADAURA) · 05 October 2026
- Lung: Metastatic NSCLC - first-line immunotherapy · 24 September 2026
- Lung: Extensive-stage SCLC - PCI · 13 September 2026
- Lung: Prophylactic cranial irradiation · 02 September 2026
- Lung: Limited-stage SCLC thoracic RT · 22 August 2026
- Lung: Stage III NSCLC - adjuvant durvalumab · 11 August 2026
- Lung: SABR fractionation · 31 July 2026
- Lung: Radical RT/SABR for early NSCLC · 20 July 2026
Weekly FRCR 2A revision email
The week's free questions and one teaching point, in one email. Unsubscribe any time. By subscribing you consent to marketing email from FRCR Vault (details in our privacy policy).